[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414559":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":36,"locations":43,"responsibleParty":85,"collaborators":87,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":111,"studyType":112,"phases":10,"briefSummary":113,"conditions":114,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Aventyn, Inc.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"COVID19 PCR positive test and negative or high risk asymptomatic",null,"Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects",{"label":13,"type":10,"description":14,"interventionNames":15},"COVID19 PCR positive test Stage 1 infection","Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)",[16],"Drug: Coromec Registry with ECL-19",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Coromec Registry with ECL-19","Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology",[13],[24],"Glycocheck",[26,30,33],{"name":27,"affiliation":28,"role":29},"Hans A Vink, PhD","Maastricht University","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Michael Castro, MD","Abrazo Health Network",{"name":34,"affiliation":32,"role":35},"Kris Vijay, MD","STUDY_CHAIR",[37,41],{"name":34,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","2317942328","coromec@aventyn.com",{"name":42,"role":38,"phone":39,"phoneExt":10,"email":40},"Navin Govind",[44,61,73],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Multiple Locations","RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-112.07404,33.44838,{"lat":56,"lon":55},[59],{"name":60,"role":38,"phone":10,"phoneExt":10,"email":10},"Puja Chandler",{"facility":45,"status":46,"city":62,"state":10,"zip":10,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Bangalore","India","IN",{"type":53,"coordinates":66},[67,68],77.59369,12.97194,{"lat":68,"lon":67},[71],{"name":72,"role":38,"phone":10,"phoneExt":10,"email":10},"Kiran Balakrishna",{"facility":45,"status":46,"city":74,"state":10,"zip":10,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Stockholm","Sweden","SE",{"type":53,"coordinates":78},[79,80],18.06871,59.32938,{"lat":80,"lon":79},[83],{"name":84,"role":38,"phone":10,"phoneExt":10,"email":10},"Alexander Eriksson",{"type":86,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[88,90,92,95],{"name":89,"class":6},"Intel Corporation",{"name":32,"class":91},"UNKNOWN",{"name":93,"class":94},"Karolinska Institutet","OTHER",{"name":96,"class":91},"ASU College of Health Solutions","100414559","covid-19-risk-assessment-for-hospitalization-outcomes-and-epidemiology-efficacy-100414559",false,"NCT04678193","COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy","COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy","COROMEC","Inclusion Criteria:\n\n* COVID-19 PCR positive\n* COVID-19 PCR negative\n* COVID-19 PCR pending\n* COVID-19 high risk score\n\nExclusion Criteria:\n\n* Subjects unwilling to participate in the study before, during or after consent\n* Patients considered unreliable by the investigator concerning the requirements for follow-up visits.",true,"ALL","18 Years",{"count":109,"type":110},27000,"ESTIMATED","2 Years","OBSERVATIONAL","Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions",[115],"Covid19","2024-03-19",{"date":118,"type":119},"2024-03-20","ACTUAL",{"date":121,"type":119},"2020-12-24",{"date":123,"type":110},"2026-06-30",{"name":5,"class":6},3]